Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 6 days ago
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Withholding NOACs prior to ablation for AF may yield brain lesions

Elvira Manzano
11 Jul 2017

Withholding new oral anticoagulants (NOACs) prior to performing left atrial radiofrequency ablation in patients with atrial fibrillation (AF) is associated with an increased risk of asymptomatic cerebral lesions, a prospective study has shown. This raises the question of whether brain lesions on MRI could lead to cognitive decline over time.

The rate of brain lesions in patients who had previously been prescribed a NOAC but went off the drug a day before ablation (standard practice at that time) was higher at 17.3 percent (p=0.049). By comparison, those who stayed on a prescribed vitamin K antagonist (VKA) therapy throughout the procedure had a 9.6 percent rate of asymptomatic, mostly small, cerebral lesions on MRI post ablation. [EHRA EUROSPACE-CARDIOSTIM 2017, abstract P247]

“The study does not imply that VKAs should be preferred over NOACs prior to AF ablation,” said lead author Dr Michael Derndorfer from the Elisabethinen University Teaching Hospital in Linz, Austria said. Rather, it underscores the importance of uninterrupted anticoagulation throughout ablation. “It was the discontinuation why we had an astonishingly high rate of asymptomatic cerebral lesions in the NOAC group.”

The study included 410 patients who had a routine cerebral MRI pre and post standard pulmonary vein isolation (PVI) for AF. Patients were on a background NOAC (rivaroxaban, dabigatran, or apixaban) or coumarin derivatives (phenprocoumon or acenocoumarol). About two-thirds had paroxysmal AF and one-third had persistent AF. Less than a third were women. The duration of AF and history of hypertension, stroke, transient ischaemic attack, and diabetes was comparable between groups.

It was standard practice previously to stop NOACs prior to ablation due to an increased risk of bleeding. However, greater experience with NOACs shifts the practice to keeping patients on anticoagulants or VKAs during the procedure even if heparin is introduced to prevent a stroke.

In the current study, larger left atrial diameter, higher stroke risk scores, and a lower achieved activated clotting time (ACT) at the time of the procedure were among the predictors of cerebral lesions. Derndorfer cannot say what the long-term effects of cerebral lesions are, but some studies suggest that they could lead to cognitive decline in the future.

Although procedural heparin was titrated to an ACT of 300 to 400 seconds according to current recommendations, the mean achieved ACT was significantly lower in those whom the NOACs were withdrawn. Left atrial procedure time in minutes was comparable between groups (179. 5 vs 171.9 for NOACs and VKA, respectively) so was distribution of PVI­ procedures. All­-cause mortality, stroke, and need for cardiac surgery intervention did not occur in both groups.

Experts said the study is unreproducible as performing pre and postprocedural MRI to check for cerebral lesions in every patient is both complex and costly. This puts a premium on weighing the available evidence concerning the risks and benefits of withholding NOACs prior to ablation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 6 days ago
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.